• FY2026 revenue of $15.8b, underlying NPATA of $3.1b
• Reported NPAT loss of $2.6b due to restructuring and impairments
• Strong demand for Ig and growth in new markets
• Operational simplification and efficiency initiatives in progress
• Maintained dividend and completed A$1b buyback

CSL Limited announced its FY2026 results, showing total revenue of $15.8 billion, an underlying NPATA of $3.1 billion, and a reported NPAT loss of $2.6 billion, primarily due to one-off restructuring costs and impairments. Despite the loss, the company reported robust demand for immunoglobulin (Ig) and strong uptake of new products like ANDEMBRY® and HEMGENIX®. CSL also made progress on operational simplification and efficiency initiatives, with cost savings of $176 million realized. The company maintained its dividend and completed a A$1 billion share buyback program.

FY27: Incremental savings, underlying NPAT growth ~5%, FX impact headwind ~$50m, impairments ~$200m

CSL expects mid-single-digit revenue growth for Behring and low single-digit growth for Seqirus in FY27, with Vifor facing headwinds. The company plans to reinvest ~50% of savings in growth opportunities and expects strong cash flow from operations.